Skip to main content
. 2016 Jan 15;90(3):1298–1310. doi: 10.1128/JVI.02167-15

TABLE 2.

Experimental design and clinical performance for swine inoculated with various doses of FMDV A12-P1 deopt

Dosea (PFU) Pig no. Clinical scoreb Viremiac RT-PCR, serumd Shedding virus RT-PCR, nasal swabe SNf at dpi:
7 14 21
103 1 0 0 N 0 N 0 2.4 2.4
2 0 0 N 0 N 0 3 1.8
3 0 0 N 0 N 1.2 2.1 2.4
105 4 0 0 N 0 N 1.8 2.4 1.8
5 0 0 N 0 N 1.5 2.1 1.8
6 0 0 N 0 N 0.9 4.2 2.7
106 7 7/1 0 WP (5–6) 0 WP (3–4) 2.1 4.8 3.9
8 3/8 0 WP (2–4) 0 WP (3–4) 3.6 4.8 3.9
9 4/11 2/2.1 × 103/1 SP (1–4) 0 WP (3–4) 3.6 4.2 3.3
107 10 2/12 1/8.8 × 102/2 SP (1–3) 0 WP (2–5) 3.6 3.6 3
11 3/12 1/4 × 102/3 SP (1–4) 0 WP (2–5) 2.7 3.9 3
12 2/8 1/8.5 × 102/3 SP (1–3) 0 WP (2–5) 2.4 2.7 3
a

Dose of inoculum per animal, expressed as number of PFU in a total volume of 0.4 ml, administered by intradermal inoculation in the heel bulb.

b

Day postchallenge for first signs of lesions/highest lesion score.

c

First day postchallenge that viremia was detected by virus isolation/maximum amount of viremia in PFU per milliliter detected in serum samples/duration (days) of viremia.

d

N, negative (CT > 40); WP, weak positive (30 ≤ CT < 40); SP, strong positive (CT < 30). The days at which virus was present are indicated in parentheses.

e

N, negative (CT > 40); WP, weak positive (30 ≤ CT < 40); SP, strong positive (CT < 30). The days at which virus was present are indicated in parentheses.

f

SN, serum neutralizing antibody titer, reported as log10 of the inverse of the serum dilution that neutralized 100 TCID50 of virus in 50% of the wells at the indicated time points.